Overview

Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions

Status:
Completed
Trial end date:
2001-12-01
Target enrollment:
Participant gender:
Summary
To compare the rate and extent of absorption of cabergoline 0.5 mg tablets (test) versus Dostinex (reference)
Phase:
Phase 1
Details
Lead Sponsor:
Par Pharmaceutical, Inc.
Collaborator:
Anapharm
Treatments:
Cabergoline